Third Harmonic Bio(THRD) - 2023 Q4 - Annual Results

Exhibit 99.1 Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, CA, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for th ...